New radiation technique aims to boost survival in aggressive blood cancers
NCT ID NCT03121014
First seen Jan 19, 2026 · Last updated May 14, 2026 · Updated 15 times
Summary
This study tests a precise type of radiation (total marrow irradiation) given with standard chemotherapy before a stem cell transplant in people with high-risk acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS). The goal is to see if this combination helps more patients stay free of their cancer for at least one year. About 38 adults aged 18-65 with hard-to-treat or poor-risk disease are being enrolled.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELODYSPLASTIC SYNDROMES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Illinois at Chicago
Chicago, Illinois, 60612, United States
Conditions
Explore the condition pages connected to this study.